Alligator Bioscience AB Stock London S.E.
Equities
0RK9
SE0000767188
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.508 SEK | -66.28% | +123.96% | +303.28% |
Sales 2024 * | 261M 24.38M | Sales 2025 * | 122M 11.42M | Capitalization | 674M 62.9M |
---|---|---|---|---|---|
Net income 2024 * | -6M -560K | Net income 2025 * | -89M -8.31M | EV / Sales 2024 * | 1.07 x |
Net cash position 2024 * | 395M 36.82M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.51 x |
P/E ratio 2024 * |
-1.95
x | P/E ratio 2025 * |
-8.87
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.28% |
Latest transcript on Alligator Bioscience AB
1 day | -66.28% | ||
1 week | +123.96% | ||
Current month | +123.96% | ||
1 month | +123.96% | ||
3 months | +101.96% | ||
6 months | +549.00% | ||
Current year | +303.28% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Bregenholt
CEO | Chief Executive Officer | 53 | 21-05-31 |
Marie Svensson
DFI | Director of Finance/CFO | 60 | 20-08-31 |
Chief Tech/Sci/R&D Officer | 56 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | 16-12-31 | |
Staffan Encrantz
BRD | Director/Board Member | 73 | 22-05-08 |
Director/Board Member | 62 | 21-05-31 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- ATORX Stock
- 0RK9 Stock